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Proximal 6q, a region showing allele loss in primary breast cancer
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Cancer Research Campaign Department ofCancer Genetics, Christie CRC Research Centre, Manchester M20 9BX, UK.
S_inmary To define regions of deletion of chromosome 6q in breast cancer, we scored 18 (CA), microsatel-
lites for allelic imbalance (AI) in 42 paired blood/tumour samples. Heterozygosity frequencies of the markers
in the sample population ranged from 31% to 92% (mean 68%). Two regions of the chromosome arm showed
Al values greater than the background range of 10-22% (mean 17%) of informative cases that was observed
with five markers spanning 6q21-q25.2. Firstly, seven markers gave Al values that averaged 35% in a region
flanked by D6S313 (Al = 10%) at 6ql3 and D6S283 (Al = 17%) at 6qI6.3-21. The second region showed
marginally increased Al at 6q25.2-q27 and included D6S193, previously shown to be close to a tumour-
suppressor gene involved in ovarian carcinoma. Since Al of 6q in breast cancer was shown previously to be
due predominantly to loss ofheterozygosity, our results suggest the presence of at least two tumour-suppressor
genes on 6q that are involved in breast cancer. The proximal region has not been recognised in breast cancer
before and is involved in a higher frequency of tumours than the distal region.
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The involvement of several tumour-suppressor genes in
cancers of the colon (Vogelstein et al., 1988), breast (Mackay
et al., 1988; Devilee et al., 1989, 1991; Cropp et al., 1990;
Sato et al., 1990), kidney (Zbar et al., 1987; Morita et al.,
1991), liver (Fujimonr et al., 1991), lung (Kok et al., 1987,
Yokota et al., 1987) and bladder (Fearon et al., 1985) has
been inferred from loss of constitutional heterozygosity
(LOH) studies using molecular analysis of polymorphic
genetic markers. In all these types of cancer, losses of multi-
ple regions have been identified.
Deletions of parts of the long arm of chromosome 6 have
been reported in breast carcinoma (Devilee et al., 1991),
ovarian carcinoma (Lee et al., 1990; Sato et al., 1990; Zheng
et al., 1991; Saito et al., 1992a; Cliby et al., 1993; Foulkes et
al., 1993) B-cell Non-Hodgkin's lymphoma (B-NHL) (Gai-
dano et al., 1992), T-cell acute lymphocytic leukaemia (T-
ALL) (Menasce et al., 1994) and malignant melanoma (Trent
et al., 1989). These results suggest the presence of one or
more tumour-suppressor genes on chromosome 6q, an idea
supported by chromosome-mediated transfer experiments
(Trent et al., 1990).
Devilee et al. (1991) reported a combined allelic imbalance
(Al) at D6S37 (6q26-q27) and MYB (6q23.3-q24) of 50%
in 42 informative patients. Furthermore, 90% of the allelic
imbalance was shown to be due to allele loss rather than
gain. Because these authors described 6q as 'the second most
frequent site after 17p for LOH in breast cancer', we have
carried out a detailed analysis of Al in malignant breast
tumours from 42 patients using 18 recently described highly
polymorphic dinucleotide repeat sequences (Weber and May,
1989; Weber, 1990) distributed along the length of 6q.
Materal and meod
Patients and tissues
Blood and tumour samples were collected from 42 unrelated
breast cancer patients with full clinical details. Their diag-
noses were infiltrating ductal in 34 patients, infiltrating
lobular in six, mucoid in one and indeterminate in one
case.
Preparation ofhigh molecular ,eight DNA
The isolation of genomic DNA from blood lymphocytes and
breast tumour tissues was performed as previously described
(Sambrook et al., 1989).
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(CA). microsatellites
Six markers (D6S239, D6S246, D6S330, D6S355, D6S357
and D6S359) were isolated and characterised in our
laboratory (Orphanos et al., 1993, 1994); nine markers
(D6S261, D6S280, D6S281, D6S283, D6S284, D6S286,
D6S297, D6S300 and D6S313) were genetically mapped by
others (Weissenbach et al., 1992); D6S220 was previously
assigned to human chromosome 6 (Hudson et al., 1992).
(CA), microsatellites for D6S186 and D6S193 loci, at 6q26
and 6q27 respectively (Saito et al., 1992b), were isolated from
cosmids generously provided by Dr Y Nakamura using the
method of Santibanez-Koref et al. (1993). Primers,
polymerase chain reaction (PCR) conditions and physical
mapping of the loci have been reported by Orphanos et al.
(1994), Menasce et al. (1994) and in Table I.
Allele analtsis
Blood and tumour DNA samples from 42 patients with
breast cancer were amplified by PCR to give radiolabelled
products and analysed as described previously (Orphanos et
al., 1993). Quantification of the autoradiographic signals was
performed with a 425S phosphorimager and Image Quant
software supplied by Molecular Dynamics. The ratio of allele
intensities in the tumour sample (T) relative to that in lym-
phocyte DNA (B) was calculated from T = Tl/T2 and B =
Bl/B2, where TI and T2 and Bi and B2 correspond to the
intensities of alleles I and 2 in the tumour and the blood
samples respectively. Factors of T/B <0.5 or T/B >2.0 were
arbitrarily considered to respresent Al evidence for LOH.
Samples that showed Al ratios close to 0.5 or 2.0 were either
rerun on a denaturating gel or their analysis was repeated
using fresh blood/tumour sample aliquots.
Table I Localisation and PCR conditions of chromosome 6 (CA),
microsatellites
Annealing
temperature
Locus Region Primer sequence (5'-*3') (°C)
Size
(bpj
D6S186 6q26 ttacccactacctacccagag 54 235
gtcccttggaaaattctccct
D6S193 6q27 agagcaggctctgcatggtta 53 190
ctgacaaaagaacatattgtttccc
D6S297 6q27 agaagtgtctctaaagataaggtcaccc 56 150
cagataactggtgaagtcaaagacc
D6S281 6q27 ccatggccctaaagttttcaag 56 190
agagacctatgtttcaggcaaaggcainsom 6q ldel loss in cancer
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Results
We studied paired blood and tumour DNA samples from 42
breast cancer patients (Table II). Examples of Al are shown
in Figure 1 for four informative patients. At D6S239 patient
42 shows no Al, whereas the tumour sample of patient 41
clearly shows an excess of the lower allele. Similarly, at
D6S297 patient 33 shows no Al but patient 32 has relatively
more of the upper allele in the tumour sample than in the
blood.
The lowest frequencies of Al occurred at 6q13 in D6S313
(10%) and over five loci in the region 6q16.3-q25.2 from
D6S283 to D6S355, where Al average 17.4% (Table II and
Figure 2). Between these two sets of loci was observed the
most frequent Al (mean = 35.3%) in a region that contained
seven loci between D6S280 at 6ql3 and D6S286 at 6ql6.3-
q21. Marginally increased Al was observed with D6S220
(26%) at 6q25.2-q27 and D6S193 (27.5%) at 6q27.
We amplified all 18 markers from the blood/tumour DNA
pairs of 20 patients and 17 markers from another six
patients. From the data shown in Table III it is evident that
in many patients Al was very extensive. Thus, patient 32
showed Al of all markers in the distal half of 6q. Patient 31
showed Al of all informative markers except D6S239 and
D6S359, which suggests that in some cases extensive Al may
be the result of deletions involving more than one chromo-
some breakage and reunion event. In other patients, namely
Table II Al of chromosome 6q in breast cancer
B Tpairs Informative
Microsatellite Localisation studied pairs (%0) AI (%)
D6S313 6q13 41 30 (73) 3/30 (10)
D6S280 6ql3 29 20 (69) 8 20 (40)
D6S239 6q13 39 27 (69) 9 27 (33)
D6S284 6ql4-ql5 39 26 (67) 5/26 (19)
D6S286 6q16.3-q21 33 29 (82) 8 27 (30)
D6S330 6ql4-ql5 39 12 (31) 6/12 (50)
D6S246 6q16.3 36 27 (75) 9/27 (33)
D6S300 6q14 42 32 (76) 11/32 (34)
D6S283 6q16.3-q21 38 30(79) 5/30(17)
D6S261 6q21 -q23.3 38 34 (89) 7/34 (21)
D6S359 6q21 -q23.3 40 37 (92) 8137 (22)
D6S357 6q21 -q23.3 40 20 (50) 2/20 (10)
D6S355 6q23.3-q25.238 24 (63) 4124 (17)
D6S220 6q25.2-q27 30 19 (59) 5119 (26)
D6S186 6q26 39 25 (64) 5 25 (20)
D6S193 6q27 40 29 (72) 8/29 (27.5)
D6S297 6q27 42 19 (45) 4/19 (21)
D6S281 6q27 40 27 (67) 5/27 (19)
D6S239 D6S297
Patient: _42 41 32 33
Sample:
patients 5, 16, 24, 25 and 28, no Al was seen, and only
single-marker A! was seen in patients 13, 18 and 39.
Using this subset of 26 patients we compared the observed
Al on 6q with the clinical parameters of histological site,
staging, node involvement and oestrogen receptor status.
Since 92% of the tumours in the subset were of ductal onrgin
compared with 81% in the total, it was not surprising to
observe that the percentage Al values for loci in the subset
reflected those seen within the data for all 42 patients sam-
ples. On the other hand, both lobular tumours (nos. 7 and
32) for which complete data were obtained showed Al at
D6S261 and D6S359, distal to the major region of imbalance
in ductal tumours. The small sample sizes did not allow us to
determine the statistical significance of these observations
and no other trends were observed.
The markers used in this study were regionally localised by
hybrid cell deletion mapping (Orphanos et al., 1994), fluo-
rescence in situ hybridisation (FISH) (Menasce et al., 1994)
and by genetic linkage (Weissenbach et al., 1992). The order
of markers given in this paper is that of the current consen-
sus map of 6q (Volz et al., 1994) for markers from D6S313
to D6S261 (cen to q21 -q23). Markers distal to D6S261 are
not on the consensus map, but their order is consistent with
the partial maps from the quoted sources. The data presented
in this paper also permit ordering of some loci by minimising
the number of obligate breaks required to produce deletion
of alleles in tumours. For example, patient 25 showed Al of
D6S261 and D6S359, implying that the likely order of the
three loci assigned to q21 -q23.3 is (cen)-261-359-357-(tel).
Similarly, from patients 4 and 8 the order (cen)-313-280-
239-(tel) is inferred for the three loci assigned to q13.
Proximal 6q (6ql3-q21) was highlighted by Lu et al.
(1993), who observed del(6q) in 10 of 22 (45%) of breast
tumours karyotyped, and by Thompson et al. (1993), who
found del(6q) in 4 of 28 (14%) of primary breast tumours.
Our results identify the proximal region 6q13-21 as the
major site of Al in 6q in malignant breast tumours. The
small sample size did not allow us to determine the statistical
significance of the low Al values of 10% and 17% obtained
LOH (%)
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Fugwe I Loss of heterozygosity shown by allelic imbalance of
(CA). nmcrosatellites. Autoradiographs of paired blood (B) and
tumour (T) samples amplified by PCR using primers for mnicro-
satellites D6S239 and D6S297. The blood samples show pairs of
alleles (heterozygosity) at both loci. Patients 41 and 32 show Al,
but patients 42 and 33 show no Al.
Figwe 2 Localisation and allelic imbalance of markers. Solid
vertical bars show the physical locaisation of the microsatellite
loci indicated by anonymous DNA segment numbers (D6S-) in
the best consensus order. Horizontal open bars indicate the fre-
quency of Al at each locus in a panel of 42 breast tumour
samples.
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Table m Al in tumours from individual patients
Patient qB3 q14-15 q16.3-21 q21-23.3 q23.3-26 q27
no. 313 280 239 284 286 330 246 300 283 261 359 357 355 220 186 193 297 281
1 0 NI X 0 X NI NI X 0 0 0 NI 0 0 NI 0 X 0
2 0 X NI 0 NI ND 0 NI 0 0 NI 0 0 X NI 0 X 0
4 X X 0 X X X X 0 0 X 0 NI 0 NI NI 0 NI NI
5 0 NI 0 0 0 NI 0 NI 0 0 0 0 0 0 0 0 NI 0
6 0 0 0 NI 0 NI 0 NI 0 0 0 NI 0 0 X X NI X
7 0 NI 0 0 0 0 0 0 NI X X 0 NI 0 0 0 NI 0
8 0 X X 0 X NI NI 0 X X X NI 0 NI 0 X NI 0
10 0 0 0 NI X NI X X 0 0 0 NI 0 NI 0 NI 0 NI
13 0 NI 0 NI 0 NI NI 0 NI 0 X NI NI NI 0 0 NI NI
16 0 0 0 NI 0 NI NI NI NI 0 0 0 NI ND 0 0 0 NI
18 NI X 0 0 ND 0 0 0 0 0 NI 0 NI NI NI 0 0 NI
19 0 ND X X NI X NI X X NI 0 X 0 NI NI 0 0 0
22 NI ND NI 0 0 NI X X 0 0 0 0 X 0 0 0 NI NI
23 0 NI NI NI 0 NI NI X X X 0 NI 0 NI NI X NI N1
24 0 ND NI NI 0 0 0 0 0 0 0 NI 0 0 0 0 NI 0
25 0 NI 0 NI 0 0 0 0 0 0 0 NI 0 0 0 0 NI 0
28 0 0 NI 0 NI NI 0 0 0 0 0 NI 0 0 0 NI 0 0
30 0 NI X X 0 NI X NI 0 0 0 0 0 0 0 0 NI 0
31 NI X 0 X NI X NI X X X 0 NI X X X NI NI X
32 0 0 NI NI 0 NI NI NI NI X NI X NI X X X X X
33 NI 0 0 0 0 X 0 0 NI 0 0 NI NI 0 NI X 0 NI
36 0 0 X 0 0 NI X 0 NI 0 0 0 NI NI 0 NI 0 0
37 0 NI NI 0 X 0 X 0 NI 0 0 NI X X 0 X 0 0
38 NI 0 NI 0 0 NI 0 0 0 0 0 0 X X X X NI X
39 0 0 0 NI X 0 0 0 0 0 0 0 0 NI 0 0 NI 0
41 X X X NI 0 NI 0 X 0 0 0 NI NI 0 0 0 NI NI
Al 9 40 33 25 18 40 33 35 21 24 13 17 22 31 21 32 27 23
(%)
Key: 0, no AI; X, AI; NI, not informative (homozygous); NJD, not determined. Bold entries maximiise regions of AI.
with the flanking markers D6S313 and D6S283 and 19%
with D6S284. If subsequent analysis of larger numbers of
patients can confirm this finding, then the presence of at least
two tumour suppressors may be implied, consistent with
there being a site of frequent translocations in melanoma at
6qll-ql3 (Trent et al., 1989) and deletions in acute lym-
phocytic leukaemia at 6ql6.3-q21 (Menasce et al., 1994).
Distal 6q was implicated as a region of high LOH by
Devilee et al. (1991), the combined LOH of D6S37 (6q27)
and MYB (6q23-q24) being 50% in 42 informative patients.
The practice of grouping loci together to obtain a combined
frequency for Al or LOH (Takita et al., 1992; Dodson et al.,
1993) is not necessarily informative because the more
markers that are involved the greater will be the additive
effect of random losses. Thus, in our study, 16 of 26 (62%)
tumours showed Al at one or more of the nine markers in
the region 6ql3-q21 (D6S313-D6S283), and 15 of 26 (58%)
tumours showed Al at one or more of the nine markers in
the distal region 6q21-q27 (D6S261-D6S281).
Region 6q27, reported to show high LOH in serous
ovarian tumours (Saito et al., 1992a), appears to show only
marginally raised LOH (27.5%) at D6S193 in our study,
suggesting that the implied associated tumour suppressor
may be of lesser importance in breast cancer than in ovarian
carcinoma.
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